RxDoctor Payments Data

Rebecca Mason, MD

Family Medicine · Fort Wayne, INNPI 1003309378

Payments from drug & device makers

$901in general payments, 2019–2025

Across 35 payments — averaging $25.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$245
  • GSK$139
  • Johnson & Johnson$125
  • AbbVie$100
  • Lilly USA, LLC$77
  • Pfizer$69
  • plus $146 from 6 others

What the payments were for

  • Food & beverage$901100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$901 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$52,166
Medicare patients
178
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide92$112,936
JardianceEmpagliflozin48$69,956
EliquisApixaban33$38,433
XareltoRivaroxaban11$18,926
OzempicSemaglutide11$17,730
Breo ElliptaFluticasone/Vilanterol20$12,888
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,740
SynthroidLevothyroxine Sodium53$5,190
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,871
Arnuity ElliptaFluticasone Furoate16$4,857
VyvanseLisdexamfetamine Dimesylate11$4,341
Gabapentin149$3,072
Atorvastatin Calcium478$2,663
Bupropion XlBupropion Hcl114$2,442
Levothyroxine Sodium300$2,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$77$112,93692 claims
PfizerEliquis$69$38,43333 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$139$25,48547 claims
Johnson & JohnsonXarelto$125$18,92611 claims
Novo NordiskOzempic$245$17,73011 claims
AbbVieSynthroid$100$5,19053 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$14$4,34111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →